$ACW CEO Steven Gourlay sat down with Sean Boss from The Watchlist to talk about the major milestones the company has already achieved in 2025. See interview here hotcopper.com.au/news/asx-news/…

$ACW team attended Women in Life Sciences Luncheon giving support to women in the industry on IWD

ACW's CEO Dr Steven Gourlay will be presenting at the ASX SMIDcaps Conference Wednesday 26th March. Attend in person at the ASX Sydney office or stream the presentation online or watch on delay. Register now via the link below. event.asx.com.au/asxsmidcapscon… $ACW #ASXSMIDcaps

$ACW CEO Dr Steven Gourlay presented to an auditorium full of interested investors plus plenty more online at the ASX SMIDCaps conference yesterday. The ASX will make a recording available at the following link: asx.com.au/investors/inve…

$ACW Great to be mentioned in The Australian discussing our exciting Alzheimers & depression programs plus commentary on other ASX listed biotechs. The article notes a US150b market for neurological disorders by 2032 - a terrific tailwind for ActinogenMed ow.ly/EPg850VraL2

$ACW Exciting news! CMO Dr Dana Hilt & CCO Andy Udell will be attending the AD/PD™ 2025 International Conference in Vienna from April 1-4 x.com/adpdnet# They’d love to connect with other interested delegates - email [email protected] to arrange a meeting #ADPD2025

$ACW A timely article by Zoe Smith in The Daily Telegraph sheds light on the impending dementia crisis in Australia. Actinogen Medical's CEO, Dr Steven Gourlay, emphasizes the urgent need for a national screening program to detect Alzheimer's disease. ow.ly/phCj50VsReF

$ACW CMO Dr Dana Hilt, and CCO Andrew Udell are participating again today at the AD/PD™ 2025 International Conference. See the link below for the insightful academic poster presented at the conference yesterday and today by Dr. Hilt: ow.ly/Se9S50VtE1m

$ACW CEO Steve Gourlay discusses the potential of Xanamem in treating Alzheimer's & depression & the significant opportunities in those markets in an interview with Proactive Investors Proactive interview: ow.ly/mCC050VunG6 ACW SMIDCaps recording: ow.ly/C2i150VunG7

$ACW is pleased to share a new Bioshares research paper on $ACW with rating 'Speculative Buy Class B' & valuable insights into our Xanamem® program including the XanaMIA ph 2b/3 Alz trial due to read out interim results later 2025 & final results in 2H26: ow.ly/urx550VvkrP

$ACW Discover why Actinogen Medical is a standout biotech investment opportunity! With our innovative approach to Alz &depression treatments, promising clinical trial data & solid financial position, this Edison video sets out their view of ACW's equity upside ow.ly/yuwI50VC3Gv

$ACW Great conversation between $ACW CEO Dr Steven Gourlay and Brandon Li on Power to the Patients diving into the work we are doing at Actinogen and the future of CNS drug development! Link to the episode here: ow.ly/ehmO50VL0La

$ACW Join our 'plain English' 1-hour webinar at 11am Sydney time tmw, 15 May. CMO Dana Hilt & panelists discuss the latest developments in the quest for effective Alz treatments & how $ACW is preparing for the future commercialization of Xanamem Register: ow.ly/zfC750VSfl2

Missed the $ACW Clinical Trials Science Forum? No problem! A recording is available. Learn about the latest advancements in Alzheimer's trials & $ACWs commercialization strategies for Xanamem & watch a new video explaining its unique mechanism of action youtu.be/QyfiLsSYQVg

$ACW CMO Dr Dana Hilt shared clinical trial results at #APA2025 showing Xanamem’s potential in treating depression & Alzheimer’s by targeting brain cortisol. Read the article & watch the interview with Psychiatric Times 👉 ow.ly/MqjB50VW6I8 #Xanamem #MentalHealth

🧠💜 $ACW Team Actinogen is joining the Sydney Memory Walk & Jog this Sunday to support 421,000 Aussies living with dementia. Help us reach our $5,000 goal for Dementia Australia—every donation counts! 🙌 Join us or donate 👉 ow.ly/yT7Y50VWPMM #MemoryWalk #DementiaAustralia

$ACW 🌟The Actinogen family demonstrated strong solidarity at the #MemoryWalkAndJog on May 25 at Sydney Olympic Park—raising over $6,000 for Dementia Australia! 💙 Thanks to our team, supporters & furry friends for making it a day to remember! 🐾 ow.ly/2mXc50VYAI0

$ACW Actinogen’s oral drug Xanamem® is making headlines in today’s Courier Mail for its potential to become the holy grail in the fight against Alzheimer's! Read more: ow.ly/kMzN50W3PjZ #Alzheimers #Biotech #Actinogen #Xanamem #MedicalBreakthrough

$ACW is presenting at Biotechnology Innovation Organization in Boston! 🗓️ June 17 | 🕓 4:45 PM | 📍 Room 153B Hear from Andrew Udell & Dr. Dana Hilt on our latest advancements and the potential of #Xanamem. They’re also meeting with companies throughout BIO — connect via the BIO portal or DM us here!